These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20002849)

  • 1. The current status of targeted therapy for non-small cell lung cancer.
    Francis H; Solomon B
    Intern Med J; 2010 Sep; 40(9):611-8. PubMed ID: 20002849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
    Agelaki S; Georgoulias V
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future].
    Bergot E; Levallet G; Zalcman G
    Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S119-26. PubMed ID: 18971836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of novel second-line targeted therapies in non-small cell lung cancer.
    Massarelli E; Herbst RS
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.
    Yoshida T; Zhang G; Haura EB
    Biochem Pharmacol; 2010 Sep; 80(5):613-23. PubMed ID: 20519133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New molecular targeted therapies integrated with radiation therapy in lung cancer.
    Provencio M; Sánchez A; Garrido P; Valcárcel F
    Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies against EGFR in non-small cell lung cancer.
    Pirker R; Filipits M
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D; Govindan R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
    Reck M; Crinò L
    Lung Cancer; 2009 Jan; 63(1):1-9. PubMed ID: 18579254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management.
    Scagliotti GV; Selvaggi G
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S137-16S147. PubMed ID: 17268351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
    Giaccone G
    J Clin Oncol; 2005 May; 23(14):3235-42. PubMed ID: 15886311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.